Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 5:67:102404.
doi: 10.1016/j.eclinm.2023.102404. eCollection 2024 Jan.

A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results

Christian Schoergenhofer  1 , Georg Gelbenegger  1 , Dzenita Hasanacevic  2 , Léa Schöner  2 , Margarete M Steiner  3 , Christa Firbas  1 , Nina Buchtele  4 , Ulla Derhaschnig  5 , Andreas Tanzmann  6 , Nina Model  2 , Julian Larcher-Senn  7 , Manuel Drost  7 , Martha M Eibl  2 , Andreas Roetzer  2 , Bernd Jilma  1
Affiliations

A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results

Christian Schoergenhofer et al. EClinicalMedicine. .

Abstract

Background: Toxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by Staphylococcus aureus that causes the life-threatening toxic shock syndrome. The development of a safe and immunogenic vaccine against TSST-1 remains an unmet medical need. We investigated the safety, tolerability and immunogenicity of a recombinant TSST-1 variant vaccine (rTSST-1v) after 1-3 injections in healthy volunteers.

Methods: In this randomised, double-blind, adjuvant-controlled, parallel-group, phase 2 trial, healthy adults aged 18-64 were randomly allocated to undergo 1-3 injections of either 10 or 100 μg rTSST-1v or Al(OH)3. The primary endpoint was safety and tolerability of rTSST-1v in the intention-to-treat population. The per-protocol population was used for the immunogenicity analysis. The trial is registered with EudraCT#: 2015-003714-24; ClinicalTrials.gov#: NCT02814708.

Findings: Between April and November 2017,140 subjects were enrolled and 126 completed the trial. rTSST-1v showed a good safety and tolerability profile. A total of 855 systemic adverse events occurred, 280 of which were suspected related adverse events, without dose dependency. Two participants were discontinued early because of allergic reactions. Seroconversion occurred in >81% of subjects within 3 months of the first immunisation which was sustained until 18 months after the third immunisation in over 70% of subjects in the pooled low-dose group and in over 85% in the pooled high-dose group.

Interpretation: rTSST-1v in cumulative doses of up to 300 μg was safe, well-tolerated and highly immunogenic. Two immunisations with 100 μg rTSST-1v provided the most persistent immune response and may be evaluated in future trials.

Funding: Biomedizinische Forschung & Bio-Produkte AG funded this study.

Keywords: Staphylococcus aureus; Superantigen; TSST-1; Toxic shock syndrome; Vaccine.

PubMed Disclaimer

Conflict of interest statement

GG, CS, CF, MMS, NB, UD, AT, and BJ declare no competing interests. Martha M. Eibl was the owner of Biomedizinische Forschung & Bio-Produkte AG. DH, LS, NM, and AR are employees of the study funder Biomedizinische Forschung & Bio-Produkte AG, a biotechnology company engaged in the development of BioMed rTSST-1v.

Figures

Fig. 1
Fig. 1
Trial profile.
Fig. 2
Fig. 2
Increase of TSST-1 binding antibody titres after the first immunisation and following the second and third immunisation in the per-protocol population divided by rTSST-1v recipients and the control group. Scatter dot blots are shown with GMTs and 95% CI.
Fig. 3
Fig. 3
In vitro inhibition of T-cell proliferation (A) and IL-2 gene expression (B) by 1000-fold and 3000-fold diluted sera in rTSST-1v recipients and the control group obtained before the first immunisation (day 0), 3 months after day 0 (idealized; = 3 months after the first immunisation), 12 months after day 0 (idealized; = 3 months after the third immunisation), and 24 months after day 0 (idealized; = 15 months after the third immunisation). Horizontal lines correspond to geometric means and 95% confidence intervals. For detailed methodology, please refer to the appendix.
Fig. 4
Fig. 4
Neutralising antibody titres for the expression of T cell-associated cytokines IFN-γ, IL-2, IL-6, and TNF-α in rTSST-1v recipients and the control group obtained before the first immunisation (day 0), 3 months after day 0 (idealized; = 3 months after the first immunisation), 12 months after day 0 (idealized; = 3 months after the third immunisation), and 24 months after day 0 (idealized; = 15 months after the third immunisation). For detailed methodology, please refer to the appendix. Horizontal lines correspond to geometric means and 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Davis J.P., Chesney P.J., Wand P.J., LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980;303(25):1429–1435. - PubMed
    1. Burnham J.P., Kollef M.H. Understanding toxic shock syndrome. Intensive Care Med. 2015;41(9):1707–1710. - PubMed
    1. Berger S., Kunerl A., Wasmuth S., Tierno P., Wagner K., Brugger J. Menstrual toxic shock syndrome: case report and systematic review of the literature. Lancet Infect Dis. 2019;19(9):e313–e321. - PubMed
    1. DeVries A.S., Lesher L., Schlievert P.M., et al. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS One. 2011;6(8) - PMC - PubMed
    1. Billon A., Gustin M.P., Tristan A., et al. Association of characteristics of tampon use with menstrual toxic shock syndrome in France. eClinicalMedicine. 2020;21 - PMC - PubMed

Associated data